FABP4 and cancer: Notably, FABP4 mediated carboplatin resistance, while its inhibition increased the sensitivity of cancer cells to carboplatin, suggesting FABP4 as a therapeutic target for combination with platinum chemotherapy in patients with advanced or recurrent disease[71] [Table 3].